Associated Papers
Observation of the characteristics of the natural course of Bietti crystalline dystrophy by fundus fluorescein angiography.
Zhang S et al.
Bmc Ophthalmology, 2021
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.
Wang Y et al.
Scientific Reports, 2020
Current perspectives in Bietti crystalline dystrophy.
García-García GP et al.
Clinical Ophthalmology (auckland, N.z.), 2019
Select a paper to view details